Jul 08, 2019
Adempas (Riociguat; Bayer/Merck & Co) Drug Overview & Product Profiles 2016-2025
Jun 25, 2019
Global Nocodazole Market Research Report 2019: CAS 31430-18-9 - ResearchAndMarkets.com
Jun 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
Jun 04, 2019
Theravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer
May 20, 2019
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
May 07, 2019
Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
May 07, 2019
Armas Pharmaceuticals Continues to Add to Portfolio With Launch of Second Oncology Injectable
May 07, 2019
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
May 06, 2019
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
Apr 02, 2019
Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference
Mar 07, 2019
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
Feb 27, 2019
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
Feb 26, 2019
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Jan 07, 2019
Syndax Highlights 2019 Clinical and Corporate Outlook
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Nov 12, 2018
The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir
Nov 05, 2018
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
Oct 25, 2018
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
Sep 12, 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine